HRT and hair loss: what hormone therapy changes, and what it leaves untouched
Three months into hormone therapy, more hair comes out in the shower, not less. In the only study to photograph and measure the same women's scalps before starting HRT and again at three and six months, the share of hairs sitting in the resting phase rose from 7.3 percent to 9.6 percent by month three.
By month six, that figure had fallen back to 7.0 percent, while the front hairline scored significantly better than it had at the start. That gap matters. A woman judging her hair only during the first few months could reach a very different conclusion from one looking at what happened by month six.
This article covers what hormone therapy has actually been measured to do to hair, which parts of the scalp changed and which did not, why the progestogen in an HRT prescription may deserve more attention than most women realize, and what menopause specialists say about using hormone therapy for hair symptoms in the first place.
- What the only study that measured it found
- The three-month dip, and why it matters
- The hairline improved. The crown did not.
- Why the progestogen may matter
- What menopause specialists actually recommend
- Where Botavive Glow fits, and where it does not
- Frequently asked questions
| What you notice | What the research shows |
|---|---|
| Shedding got worse after you started HRT | Resting-phase hairs rose from 7.3 percent to 9.6 percent at three months, then returned to 7.0 percent at six months |
| Your hair feels more anchored than it did | The force needed to pull out a resting hair rose from 49.7 to 63.6 grams over six months, an increase of about 28 percent |
| The front looks better but the top looks the same | Frontal hairline scores improved significantly by six months. Crown scores finished exactly where they started |
| Your hair is not visibly thicker | Hair density, hair thickness and growth rate showed no significant change across the six months |
| A friend on HRT had a different experience | Different progestogens interact differently with the androgen receptor, so two HRT regimens are not necessarily equivalent from a hair perspective |
What the only study that measured it found
Most of what you can read online about hormone therapy and hair is frustratingly vague. Clinic pages say HRT may help. Forums contain stories from women who say it helped dramatically and others who say shedding became worse. Very little of that discussion rests on researchers actually counting and measuring hairs before and after treatment.
In 2023, a team led by Yujiro Endo published one of the few studies to do exactly that. Eleven postmenopausal Japanese women aged 47 to 56 were photographed and evaluated with phototrichograms before starting hormone therapy, then again at three months and six months.
The women received oral estrogen, either 0.625 mg of conjugated estrogens or 1.0 mg of 17-beta-estradiol daily, plus 10 mg of dydrogesterone cyclically for fourteen days each month.
Most of them had not come to the clinic because of their hair. Six of the eleven had not noticed thinning at all. They were starting treatment for menopausal symptoms, and their scalps were measured along the way.
Several things changed. Others did not.
Resting-phase hairs increased at three months, then returned close to where they started. The force required to pluck a resting hair climbed steadily, from 49.7 grams at baseline to 53.5 grams at three months and 63.6 grams at six months.
The frontal hairline also improved on the study's four-point thinning scale, moving from 1.91 at baseline to 1.24 at six months.
The crown was different. Its thinning score finished at 1.61, exactly where it had started.
Hair density did not significantly change. Hair thickness did not significantly change. Growth rate did not significantly change.
That distinction matters. In this small study, hormone therapy changed some characteristics of the hair cycle and improved the appearance of the frontal hairline, but it did not produce a measurable increase in how much hair was on the scalp or how thick each strand was.
The study was a pilot involving only eleven women and had no untreated control group. It cannot tell us how much of the six-month change was caused by hormone therapy, how widely the findings apply to other women, or whether different HRT formulations would produce the same result.
It is useful evidence, but it is early evidence.
The three-month dip, and why it matters
The rise in resting hairs at three months may be the most practically useful finding in the study.
Hair grows in cycles. A follicle spends years in an active growing phase, enters a transition phase, then spends several months resting before releasing the strand and beginning another cycle.
When the timing of that cycle changes, more follicles can enter the resting phase around the same time. Weeks or months later, that can become visible as increased shedding.
Botavive covers that process in more detail in telogen effluvium: how long the shedding lasts after 40.
The Endo study does not prove that starting HRT triggered a synchronized hair-cycle shift. It simply shows that the percentage of resting hairs increased at three months and returned close to baseline by six months while hair anchoring improved over the same period.
That makes the timing important.
If shedding appears worse during the first few months after beginning hormone therapy, the three-month mark may not tell you what the longer-term pattern will be. In this small study, the picture at six months looked very different from the picture at three months.
That does not mean every woman should expect temporary shedding or that worsening hair should simply be ignored. New or significant hair loss deserves evaluation, particularly if it is rapid, patchy, associated with scalp symptoms, or continues to progress.
The hairline improved. The crown did not.
The difference between the front of the scalp and the crown is one of the most interesting findings in the study.
Female pattern hair loss often becomes most noticeable through the center and crown of the scalp. The part widens. More scalp becomes visible under overhead light. Individual follicles gradually produce finer hairs through a process called miniaturization.
Botavive's guide to DHT and menopause hair loss explains that process in more detail.
In the Endo study, the crown thinning score did not improve over six months of hormone therapy.
The frontal hairline did.
Those two areas can also thin for very different reasons. Hairline and temple changes may involve female pattern hair loss, years of traction from hairstyles, breakage, or conditions such as frontal fibrosing alopecia.
Botavive covers those distinctions in hair thinning at the temples: three causes in women over 40.
The study does not tell us why the frontal region improved while the crown did not. It simply shows that the response was not uniform across the scalp.
That is useful to know because "Is HRT helping my hair?" may be too broad a question.
A better question may be: what exactly is changing?
Shedding?
The front hairline?
The width of the part?
Strand thickness?
Overall density?
Those are different outcomes, and hormone therapy may not affect all of them in the same way.
Why the progestogen may matter
Two women can both say they are taking HRT while receiving quite different hormone combinations.
One overlooked variable is the progestogen.
For women with a uterus, a progestogen is generally used alongside systemic estrogen to protect the uterine lining. But the medications grouped under the term "progestogen" are not pharmacologically identical.
In a review of their pharmacology, Régine Sitruk-Ware described major differences between different synthetic progestins, including how strongly they interact with androgen receptors.
Some are derived from testosterone and can have androgenic activity. Others have little androgenic activity or even partial anti-androgenic activity.
That matters because androgen signaling is involved in follicle miniaturization in androgen-sensitive hair loss.
| Progestogen | Chemical family | Androgen-receptor profile | Why it may matter |
|---|---|---|---|
| Norethisterone, also called norethindrone | 19-nortestosterone, estrane group | Testosterone-derived, with androgenic potential | Its androgen-receptor activity differs from less androgenic progestogens |
| Levonorgestrel | 19-nortestosterone, gonane group | Testosterone-derived, with androgenic potential | It is also used in some intrauterine systems and differs pharmacologically from other progestogens |
| Desogestrel, gestodene, norgestimate | Gonane group, later-generation molecules | Derived from the same broader chemical family but with different receptor activity | Their effects cannot be assumed to be identical to older testosterone-derived progestins |
| Drospirenone | Spironolactone-derived | No androgenic effect and partial anti-androgenic activity | Its receptor profile is substantially different from androgenic progestins |
| Dienogest | Hybrid estrane molecule | No androgenic effect and partial anti-androgenic activity | Its chemical ancestry does not predict identical receptor behavior |
| Trimegestone, nomegestrol acetate | 19-norprogesterone derivatives | Predominantly progestational with little or no androgenic activity | Their androgen-receptor profile differs from testosterone-derived options |
There are important limits to that table.
It describes pharmacology, not proven hair outcomes. No clinical trial has compared these progestogens head to head using hair loss or hair growth as the primary endpoint.
It also does not mean an androgenic progestogen will cause hair loss in a particular woman or that an anti-androgenic one will improve it.
What it does show is that asking only "Is HRT good or bad for hair?" leaves out an important part of the prescription.
If hair changes begin after starting or changing hormone therapy, it may be reasonable to ask your prescriber exactly which estrogen and which progestogen you are using and whether the formulation could be relevant.
Interestingly, the small Endo study that found improvement in the frontal hairline used dydrogesterone alongside estrogen.
What menopause specialists actually recommend
A 2022 consensus paper published in Climacteric, the journal of the International Menopause Society, reviewed changes to skin and hair associated with menopause.
The authors describe reduced scalp hair growth and density, changes in hair quality and structure, and increased unwanted facial hair.
That combination may feel particularly unfair: less hair where you want it and more where you do not.
Botavive covers why those changes can appear together in menopause facial hair: why it arrives at the same time your scalp hair thins.
The consensus paper also makes an important point about treatment.
Hormone replacement therapy is not recommended solely for skin and hair symptoms because the decision to use systemic hormone therapy requires a broader assessment of benefits and risks.
Where a woman is already considering HRT for menopausal symptoms, however, potential effects on skin and hair can reasonably be part of the discussion.
That is a more useful way to frame the question.
Hair can be part of the conversation about hormone therapy. It should not be the only reason for the decision.
If you are weighing hormone therapy more broadly, Botavive's article on what the drop in hormone therapy use means if you are not taking it covers the wider picture, while low estrogen symptoms in women over 40 explains how declining estrogen can show up across the body.
Where Botavive Glow fits, and where it does not
Hormone therapy and nutritional support do different jobs.
Botavive Glow is not a treatment for female pattern hair loss, frontal fibrosing alopecia, telogen effluvium, or any other diagnosed hair-loss condition. A widening part, rapidly receding hairline, patchy loss, scalp inflammation, or persistent unexplained shedding deserves medical evaluation.
What nutrition can support is the biological work involved in producing and maintaining normal hair.
Hair follicles are metabolically active structures. Building keratin, maintaining connective tissue around the follicle, protecting cells from oxidative stress, and supporting normal cell division all depend on adequate nutrient status.
Botavive Glow was formulated for the hair, skin and nail needs of women 40+, with nutrients and botanicals including biotin, vitamin C, zinc, bamboo silica, saw palmetto, stinging nettle and hyaluronic acid.
It is designed as nutritional support, not as a substitute for diagnosis, medical treatment, or hormone therapy.
Botavive's guide to why biotin is the weakest ingredient in most hair, skin and nails formulas explains why looking at the full formula matters more than simply choosing the bottle with the largest biotin number on the front.
Frequently asked questions
Does HRT help with hair loss?
The evidence is limited. In a small study of eleven postmenopausal women, six months of hormone therapy improved frontal hairline appearance and increased how firmly resting hairs were anchored, but did not significantly change overall hair density, strand thickness or growth rate. The study had no untreated control group, so the findings should be considered preliminary. Menopause specialists do not recommend systemic hormone therapy solely for hair symptoms.
Can HRT cause hair shedding?
In the Endo study, the percentage of hairs in the resting phase increased at three months before returning close to baseline at six months. That means an early increase in shedding is consistent with what was measured in this small group, although the study cannot establish how common this is or whether HRT caused the change. New or persistent shedding should be discussed with a healthcare professional.
How long does it take to see hair changes on hormone therapy?
The limited published data suggest that three months and six months can look quite different. In the Endo study, resting-phase hairs were highest at three months, while the significant improvement in frontal hairline score was seen at six months. That does not establish a universal timeline, but it does show why conclusions drawn very early in treatment may not reflect the later pattern.
Will HRT bring back density at my crown?
The available evidence does not show that. In the Endo study, the crown thinning score was unchanged after six months, and there were no significant improvements in overall hair density or strand thickness. Crown thinning can have several causes, including follicle miniaturization associated with female pattern hair loss, so persistent changes are worth discussing with a dermatologist.
Does the type of HRT matter for hair?
Potentially. Different progestogens have different androgen-receptor activity, and not all HRT regimens are pharmacologically equivalent. However, clinical trials have not directly compared different HRT formulations for hair outcomes. If hair changes begin after starting or changing treatment, ask your prescriber which estrogen and progestogen you are using and whether the formulation could be relevant.
Can I use nutritional hair support while taking hormone therapy?
Dietary supplements and hormone therapy work through different mechanisms. Tell your healthcare professional about all supplements you use, especially if you take prescription medications or have medical conditions. Nutritional support does not replace evaluation or treatment for persistent or progressive hair loss.
Sources
- Endo Y, Obayashi Y, Murakoshi M, Saito J, Ueki R, 2023. Pilot study of 11 postmenopausal women measuring telogen rate, plucking strength, thinning scores, density and thickness before HRT and at three and six months. International Journal of Women's Dermatology 9(4):e109. pmc.ncbi.nlm.nih.gov/articles/PMC10615536
- Zouboulis CC and colleagues, 2022. Consensus review of menopausal skin and hair changes, including recommendations concerning hormone therapy for skin and hair symptoms. Climacteric 25(5):434-442. pubmed.ncbi.nlm.nih.gov/35377827
- Sitruk-Ware R, 2004. Review of the pharmacological profiles of progestins used in contraception and menopausal hormone therapy, including androgenic and anti-androgenic activity by chemical family. Maturitas 47(4):277-283. pubmed.ncbi.nlm.nih.gov/15063480